Curebase Stock
Curebase is a provider of decentralized clinical research software solutions and services to patients and medical providers.
Sign up today and learn more about Curebase Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Curebase Stock
Curebase builds a digital clinical trial assistant that would alter how medical providers discover, activate, and administer clinical trials for their patients. It aims to run clinical trials faster and cheaper than anyone else via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. The company was established in 2017 and is based in San Francisco, California.
Investors
Bold Capital Partners
Liquid 2 Ventures
Whatnot, Cerebral, Newfront Insurance, Swiftly, Mux, Parsley Health, Curebase
Funding History
| August 2018 | $120K |
|---|---|
| October 2018 | $2.5M |
| May 2021 | $15.0M |
Management
Founder & CEO
Tom Lemberg
CTO
Matthew Rials
Investor
Jeff Richards
Vice President Of Business Development
Wayne Bowden
Chief Operating Officer
Storm Stillman
Press
TechCrunch - Aug, 22 2018
All 59 startups that launched today at Y Combinator’s S18 Demo Day 2EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
